Dear All (and with thanks to ATMF’s Damiano de Felice for co-authoring this newsletter), Last week, the team at ATMF (Access to Medicine Foundation) released a 3rd update to the AMR Benchmark series that they started in 2018. For those not familiar with the ATMF, its independent analyses (all its funding is from governments or private
Dear All, WHO have released for consultation an updated draft of their EML (Essential Medicines List) Antibiotic handbook. For those not familiar with it, WHO’s EML (now in its 22nd edition!) provides a guide to a core set of medicines that every country should have. The antibiotic-focused version does this for antibiotics and then adds
Dear All, The US Department of Defense (DoD) is offering funds through the Small Business Innovation Research (SBIR) program for a “Novel Antibiotic for the Treatment of Multidrug-Resistant Pseudomonas Aeruginosa Infections.” Antibody, phage, and vaccine approaches are out of scope and the business must be located in the United States. To find the funding offer, navigate
Dear All, Breaking news! Prior newsletters (initial and follow-up) have discussed the UK’s innovative antibiotic subscription pilot (aka, “Netflix for antibiotics”). In brief, the UK intends to identify two innovative antibiotics suitable for being purchased via a delinked model in which the payment to the innovator is a fixed annual fee rather than a per-use
Dear All (and with thanks to Kevin Outterson for authoring this newsletter), Readers of these newsletters will need few reminders of why pull incentives are critical to restoring the R&D ecosystem for antibacterials. (But if you are new to the issue, Andrew Jack’s 5-minute video explainer is a great start; see also this annotated list
Dear All, Three global conversations to put on your listen-to-this list! One is this coming week, one is during ECCMID, and one is a video you can listen to now! First up and happening in just a few days on Thursday 29 Apr (10a-6p EST), please mark your calendar for a UN General Assembly High-Level interactive
Dear All, I was fascinated to see Mayo Clinic’s Global Bridges Healthcare Alliance release an RFP on 21 Oct entitled “Antimicrobial Stewardship (AMS) Programs to Address Health Inequities arising from Socioeconomic Disparities in USA, Europe, Japan, South Korea, Australia and New Zealand.” The RFP is supported by a grant from Pfizer and seeks to “… solicit programs that have
Dear All, WHO continues on their streak of seeking support for their AMR-related work! Today we have a posting by the Tripartite Joint Secretariat on Antimicrobial Resistance (AMR) of a consultancy opening for an 11-month project that would support development of multisectoral guidance(s) on development and strengthening of the coordination mechanisms and governance structures for addressing AMR. Full details
Dear All, A brief note today as I am traveling (yes, really … first time in almost 18 months) but wanted to share these 3 important upcoming meetings. The theme I expect to hear running through them all is that (i) innovation is possible (the CARB-X Year 5 report is amazing!), (ii) new antibiotics must both
Dear All, I think the importance of this is self-explanatory (go here for the .pdf information pack): “The Department of Health and Social Care is seeking to make 6 appointments to the Advisory Committee on Antimicrobial Prescribing, Resistance and Healthcare Associated Infections (ARPHAI). ARPHAI is a UK-wide, independent, non-executive advisory committee, which provides practical and scientific advice
